Dr. Aju Mathew
is a Medical Oncologist, Haematologist, Internist and Epidemiologist practising in Kochi
Dr. Aju Mathew is a medical oncologist, haematologist, internist and epidemiologist practising in Kochi.
Multiple sclerosis MS is the most common c... more»Multiple sclerosis MS is the most common chronic inflammatory disease of the CNS with more than 2 million individuals affected globally. In this article, Dr Aju Mathew discusses a study and explains the relationship between EBV in multiple sclerosis. «less
Oct 03, 2022
Critical illness decreases vitamin C conce... more»Critical illness decreases vitamin C concentration in the plasma due to the abrupt release of oxidants in response to sepsis. This article discusses various studies that were conducted to understand the effect of Vitamin C administration in critical care. «less
Sep 05, 2022
On October 1st, two pharmaceutical compani... more»On October 1st, two pharmaceutical companies announced the launch of a take-at-home oral pill that can reduce the risk of severe COVID by 50%. Though vaccination continues to remain our first line of defence against SARS-CoV-2, this new drug may show COVID the door. th «less
Oct 15, 2021
This week, Dr. Aju Mathew writes on the mo... more»This week, Dr. Aju Mathew writes on the most important keyword in coronary artery disease management- lipids. He highlights major studies on lipid-lowering therapies such as statins and PCSK9 inhibitors and quotes a few instances of using them in his practice. «less
Sep 03, 2021
The COVID-19 pandemic has affected all age... more»The COVID-19 pandemic has affected all age groups of the population around the globe. Children are one of the most affected groups. Dr. Aju Mathew lists the consequences that children and adolescents may face directly or indirectly due to COVID, which may last a long time. «less
Aug 13, 2021
Dr. Aju Mathew, in this second part of the... more»Dr. Aju Mathew, in this second part of the exclusive series on breast cancer for M3 India, writes on considerations that need to be employed for ovarian function suppression (OFS), a new adjuvant therapy, touted to be an effective treatment for breast cancer in young women. «less
Aug 11, 2020
